GlassScriptPhysician profile
Tyler Clay Flaningham
NPI 1538369053
$7,371.90
in general payments reported to CMS, 2019-2025
31 companies · $829 in 2025
The $829 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $434 · 2021: $230 · 2022: $1,114 · 2023: $1,499 · 2024: $1,912 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,239.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.24 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $846.25 | 2022-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $604.87 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $440.14 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $391.06 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $367.89 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $364.04 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $359.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $320.38 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $280.52 | 2019-2024 | Lybalvi, Aristada |
| Allergan, INC. | $243.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.79 | 2019-2024 | Trintellix |
| Bausch Health US, LLC | $219.43 | 2019-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $185.32 | 2019-2021 | |
| Axsome Therapeutics, INC. | $147.50 | 2023-2025 | Auvelity, Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $139.98 | 2020 | |
| Neos Therapeutics, LP | $135.41 | 2019-2025 | Adzenys Xr-Odt |
| Corium, LLC | $128.27 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $102.25 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $98.64 | 2019-2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $93.46 | 2019-2024 | |
| Shire North American Group INC | $72.55 | 2019 | |
| Orexo US, INC. | $71.64 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $41.29 | 2019 | |
| Tris Pharma INC | $41.02 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.28 | 2023 | |
| Tonix Medicines, INC. | $23.58 | 2025 | Tonmya |
| Indivior INC. | $23.54 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $21.00 | 2019 | |
| Noven Therapeutics, LLC | $17.75 | 2023 | Xelstrym |
| Eisai INC. | $16.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Flaningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.